유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카의 요로감염(UTI) 백신 시장 : 백신 유형별, 표적 병원체별, 연령층별, 투여 경로별, 판매 채널별

Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market is estimated to be valued at USD 62,785.9 Thousands in 2026 and is expected to reach USD 115,476.0 Thousands by 2033, growing at a compound annual growth rate (CAGR) of 11.2% from 2026 to 2033.

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is expected to grow at a significant rate during the forecast period owing to the increasing burden of recurrent UTIs, growing antimicrobial resistance and the need for alternatives to repeated antibiotic use. The vaccine development is primarily focused on pathogens such as Escherichia coli, with whole-cell, subunit and conjugate approaches gaining interest in the clinical and research pipelines.

The regional market opportunities are dependent on healthcare infrastructure, disease prevalence, regulatory environments and the availability of preventive therapies. Europe and Asia Pacific will continue to be key markets due to mature healthcare systems and increasing clinical development activities whereas Latin America and the Middle East & Africa are emerging markets with growing healthcare access and uptake of novel preventive therapies.

Market Dynamics

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is primarily driven by rising incidence of recurrent UTIs and growing antimicrobial resistance, which is increasing the need for preventive approaches beyond repeated antibiotic treatment. Advances in vaccine research, growing investment in bacterial vaccine candidates, and increasing clinical focus on Escherichia coli and other uropathogens are supporting market development across key regions.

However, a number of constraints are present in the market, such as limited availability of approved UTI vaccines, long clinical development timeframes and uncertain efficacy across a wide range of bacterial strains. Nevertheless, significant opportunities exist in vaccines targeting recurrent and drug-resistant UTIs, particularly among high-risk adult and elderly populations.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include INMUNOTEK S.L., OM Pharma SA, Sequoia Vaccines, Inc., GlaxoSmithKline Biologicals SA, Strathmann GmbH & Co. KG, Legacy Pharmaceuticals Switzerland GmbH, CureVac SE, Janssen-Cilag International NV, Sanofi, and GlycoVaxyn AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market

Market Segmentation

• Vaccine Type Insights (Revenue, USD Th, 2021 - 2033)
• Bacterial whole-cell Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• Live-Attenuated Vaccines
• Others
• Pathogen Targeted Insights (Revenue, USD Th, 2021 - 2033)
• Escherichia coli
• Klebsiella pneumoniae
• Pseudomonas aeruginosa
• Other Targeted Pathogens
• Age Group Insights (Revenue, USD Th, 2021 - 2033)
• Pediatric
• Adults
• Elderly
• Route of Administration Insights (Revenue, USD Th, 2021 - 2033)
• Parenteral
• Oral
• Sublingual
• Intranasal
• Sales Channel Insights (Revenue, USD Th, 2021 - 2033)
• Hospitals and Clinic Pharmacies
• Retail pharmacies
• Others
• Key Players Insights
• INMUNOTEK S.L.
• OM Pharma SA
• Sequoia Vaccines, Inc.
• GlaxoSmithKline Biologicals SA
• Strathmann GmbH & Co. KG
• Legacy Pharmaceuticals Switzerland GmbH
• CureVac SE
• Janssen-Cilag International NV
• Sanofi
• GlycoVaxyn AG

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type
  • Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Pathogen Targeted
  • Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Age Group
  • Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Route of Administration
  • Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Sales Channel

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Market Opportunities
• Regulatory Scenario
• Industry Trends

4. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Vaccine Type, 2021-2033, (USD Th)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Bacterial whole-cell Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Subunit Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Conjugate Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Live-Attenuated Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

5. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Pathogen Targeted, 2021-2033, (USD Th)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Escherichia coli
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Klebsiella pneumoniae
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Pseudomonas aeruginosa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Other Targeted Pathogens
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

6. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Age Group, 2021-2033, (USD Th)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Elderly
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

7. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Route of Administration, 2021-2033, (USD Th)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Sublingual
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

8. Europe, Asia Pacific, Latin America, Middle East & Africa Urinary Tract Infection (UTI) Vaccine Market, By Sales Channel, 2021-2033, (USD Th)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals and Clinic Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Retail pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Th)

9. Competitive Landscape

• Company Profile
  • INMUNOTEK S.L.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • OM Pharma SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sequoia Vaccines, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline Biologicals SA
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Strathmann GmbH & Co. KG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Legacy Pharmaceuticals Switzerland GmbH
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • CureVac SE
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Janssen-Cilag International NV
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlycoVaxyn AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us